Search

Displaying results 9711 - 9720 of 9731 in total
  1. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor … [A262566] Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    [L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid].

  3. Drug

    Orelabrutinib

    go.drugbank.com/drugs/DB16272
    Investigational

    Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).

  4. Drug

    Veliflapon

    go.drugbank.com/drugs/DB16346
    Investigational

    Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).

  5. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered

  6. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    Levacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid [leucine]. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo. … , after which animal studies showed that the L-enantiomer (i.e. levacetylleucine) has potential clinical benefits compared to the racemic mixture.

    Synonyms: Acetyl-l-leucine, Acetylleucine, l-
  7. Drug

    Nutlin-3

    go.drugbank.com/drugs/DB17039
    Experimental

    Nutlin-3 is a small molecule inhibitor that targets p53-Mdm2 interaction.[A253057]

  8. Drug

    PHA-767491

    go.drugbank.com/drugs/DB17043
    Investigational

    PHA-767491 is a Cdc7/CDK9 inhibitor.[A253077]

  9. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]

  10. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [A264768] Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis. … Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis.